MAP2K7 and non-small cell lung carcinoma: Furthermore, combined treatment with the SHP2 inhibitor TNO155 plus a covalent KRAS G12C inhibitor achieved the effective and sustained inhibition of cell growth and MEK-ERK pathway activation in KRAS-mutated NSCLC cells [104].